Youcheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Youcheng Zhang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Feng-Xian Wei
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China
5 shared publications Hongyang Deng
The Second Clinical Medical College of Lanzhou University
4 shared publicationsHangzhi Wei
3 shared publicationsJipin Li
The Second Clinical Medical College of Lanzhou University
3 shared publicationsQi Xiao
The Second Clinical Medical College of Lanzhou University
3 shared publicationsWei Han
Department of General Surgery, Hepatic-biliary-pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, China
3 shared publications
Latest Publications
- 2 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 830, 154197
COP9 signalosome 8 mediated autophagy drives proliferation, invasion, and metastasis in pancreatic ductal adenocarcinoma
- 2 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 830, 154197
COP9 signalosome 8 mediated autophagy drives proliferation, invasion, and metastasis in pancreatic ductal adenocarcinoma
- Open Access
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1826297
GLIS3 drives epithelial–mesenchymal transition and cancer stem–like traits in stomach adenocarcinoma via TGFBR3–Hedgehog signaling
Background: GLIS family zinc finger 3 (GLIS3) is a transcription factor implicated in multiple malignancies, but its role in stomach adenocarcinoma (STAD) and its downstream effector axis remain unclear. We investigated whether GLIS3 coordinates epithelial–mesenchymal transition (EMT) and cancer stem cell (CSC)-like programs in STAD through a signaling cascade. Methods: GLIS3 expression and prognostic associations were analyzed using transcriptomic datasets from The Cancer Genome Atlas, Genotype-Tissue Expression, and Gene Expression Omnibus. GLIS3 protein levels were evaluated by immunohistochemistry in 133 paired STAD tissues. Survival was assessed by Kaplan–Meier analysis together with multivariable regression models. Gain- and loss-of-function studies were performed in AGS and HGC-27 cells to evaluate proliferation, migration, EMT and CSC-like phenotypes. Mechanistic experiments interrogated a GLIS3–transforming growth factor beta receptor 3 (TGFBR3)–Hedgehog axis using ChIP-qPCR, dual-luciferase assays, co-immunoprecipitation, GLI reporter assays, and vismodegib treatment. Tumor growth was assessed in xenograft models. Results: GLIS3 was consistently upregulated in STAD across public datasets and in the clinical cohort (median H-score: 112 vs 39, P < 0.001) and was associated with adverse clinicopathological features and poor survival. In the TCGA cohort, higher GLIS3 expression was associated with greater nodal burden, more advanced nodal and metastatic status, and worse vital status. In multivariable Cox models restricted to cases with defined stage classifications, GLIS3 remained independently associated with worse overall survival in the primary model (hazard ratio = 1.45, 95% confidence interval: 1.04–2.02; P = 0.031), with a consistent result in the sensitivity model. Functionally, GLIS3 enhanced proliferation and migration and promoted EMT marker switching and CSC-like traits. Mechanistically, GLIS3 transcriptionally activated TGFBR3 and increased Hedgehog pathway activity; bidirectional rescue experiments showed that TGFBR3 overexpression partially restored, whereas TGFBR3 silencing attenuated, GLIS3-driven EMT/CSC-like phenotypes and growth-related functions. Xenograft experiments supported an in vivo growth-promoting role of the GLIS3–TGFBR3–Hedgehog axis. Conclusions: GLIS3 identifies an aggressive STAD phenotype and engages a TGFBR3–Hedgehog program linked to EMT and CSC-like features. These findings support further evaluation of GLIS3 as a biomarker for risk stratification and provide a rationale for biomarker-guided targeting of the GLIS3–TGFBR3–Hedgehog axis in STAD.
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1826297
Open AccessGLIS3 drives epithelial–mesenchymal transition and cancer stem–like traits in stomach adenocarcinoma via TGFBR3–Hedgehog signaling
Background: GLIS family zinc finger 3 (GLIS3) is a transcription factor implicated in multiple malignancies, but its role in stomach adenocarcinoma (STAD) and its downstream effector axis remain unclear. We investigated whether GLIS3 coordinates epithelial–mesenchymal transition (EMT) and cancer stem cell (CSC)-like programs in STAD through a signaling cascade. Methods: GLIS3 expression and prognostic associations were analyzed using transcriptomic datasets from The Cancer Genome Atlas, Genotype-Tissue Expression, and Gene Expression Omnibus. GLIS3 protein levels were evaluated by immunohistochemistry in 133 paired STAD tissues. Survival was assessed by Kaplan–Meier analysis together with multivariable regression models. Gain- and loss-of-function studies were performed in AGS and HGC-27 cells to evaluate proliferation, migration, EMT and CSC-like phenotypes. Mechanistic experiments interrogated a GLIS3–transforming growth factor beta receptor 3 (TGFBR3)–Hedgehog axis using ChIP-qPCR, dual-luciferase assays, co-immunoprecipitation, GLI reporter assays, and vismodegib treatment. Tumor growth was assessed in xenograft models. Results: GLIS3 was consistently upregulated in STAD across public datasets and in the clinical cohort (median H-score: 112 vs 39, P < 0.001) and was associated with adverse clinicopathological features and poor survival. In the TCGA cohort, higher GLIS3 expression was associated with greater nodal burden, more advanced nodal and metastatic status, and worse vital status. In multivariable Cox models restricted to cases with defined stage classifications, GLIS3 remained independently associated with worse overall survival in the primary model (hazard ratio = 1.45, 95% confidence interval: 1.04–2.02; P = 0.031), with a consistent result in the sensitivity model. Functionally, GLIS3 enhanced proliferation and migration and promoted EMT marker switching and CSC-like traits. Mechanistically, GLIS3 transcriptionally activated TGFBR3 and increased Hedgehog pathway activity; bidirectional rescue experiments showed that TGFBR3 overexpression partially restored, whereas TGFBR3 silencing attenuated, GLIS3-driven EMT/CSC-like phenotypes and growth-related functions. Xenograft experiments supported an in vivo growth-promoting role of the GLIS3–TGFBR3–Hedgehog axis. Conclusions: GLIS3 identifies an aggressive STAD phenotype and engages a TGFBR3–Hedgehog program linked to EMT and CSC-like features. These findings support further evaluation of GLIS3 as a biomarker for risk stratification and provide a rationale for biomarker-guided targeting of the GLIS3–TGFBR3–Hedgehog axis in STAD.
- Open Access
- 16 January 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (4) , 5096-5111
Density Functional Theory Analysis of Luteolin Molecular Structure and Spectrum
Luteolin is a natural flavonoid compound. Numerous studies have demonstrated that luteolin exhibits pharmacological activities such as antioxidant and antitumor effects; however, the molecular mechanisms linking its electronic structure to pharmacological activities have not been systematically elucidated. Structure determines properties, which are crucial factors for investigating the chemical characteristics and reaction mechanisms. This study aims to analyze its electronic structure parameters and reveal the correlation between active sites and biological functions by using density functional theory. The geometric configuration of luteolin was optimized by the B3LYP-D3(BJ)/6–311G(d,p) method. Frontier molecular orbitals (FMOs), electron affinity (EA), ionization energy (ionization potential (IP)), density of states (DOS), bond dissociation energy (BDE), proton affinity (PA), molecular surface electrostatic potential (MESP), and vibrational spectra were calculated. The chemical shifts of 1H NMR and 13C NMR were predicted using the gauge-including atomic orbital theory. Results show that geometric optimization and spectral analysis confirm the presence of hydrogen bonds and conjugated systems in luteolin, indicating that its antioxidant and antitumor potential are closely associated with the electron delocalization capacity of the conjugated backbone and the stability modulation of intramolecular hydrogen bonds. DOS analysis reveals that the p-orbital-dominated conjugated system is the core of its chemical stability and antioxidant activity; functional groups such as carbonyl and hydroxyl groups participate in electronic state construction through p-orbital hybridization/conjugation, ultimately determining the molecular structure–function relationship. With a narrow HOMO–LUMO energy gap (4.37 eV), low BDE (304.27 kJ/mol), and low IP (724.44 kJ/mol), luteolin synergistically and efficiently scavenges free radicals via a hydrogen atom transfer-dominated mechanism, combined with sequential proton loss electron transfer (SPLET) and single electron transfer followed by proton transfer (SET-PT), suggesting potent antioxidant and antitumor capabilities. Based on the low BDE (304.27 kJ/mol) and the distribution of electrophilic/nucleophilic regions in MESP analysis, the phenolic hydroxyl group on ring B (O20–H30) and the carbonyl group on ring C (C3O11) are identified as potential key active sites for antioxidant and antitumor activities. This study investigates the structural characteristics, spectral properties, and key active sites of luteolin, providing a theoretical basis for its antioxidant and antitumor pharmacological effects and offering theoretical guidance for its targeted drug design.
- 16 January 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (4) , 5096-5111
Open AccessDensity Functional Theory Analysis of Luteolin Molecular Structure and Spectrum
Luteolin is a natural flavonoid compound. Numerous studies have demonstrated that luteolin exhibits pharmacological activities such as antioxidant and antitumor effects; however, the molecular mechanisms linking its electronic structure to pharmacological activities have not been systematically elucidated. Structure determines properties, which are crucial factors for investigating the chemical characteristics and reaction mechanisms. This study aims to analyze its electronic structure parameters and reveal the correlation between active sites and biological functions by using density functional theory. The geometric configuration of luteolin was optimized by the B3LYP-D3(BJ)/6–311G(d,p) method. Frontier molecular orbitals (FMOs), electron affinity (EA), ionization energy (ionization potential (IP)), density of states (DOS), bond dissociation energy (BDE), proton affinity (PA), molecular surface electrostatic potential (MESP), and vibrational spectra were calculated. The chemical shifts of 1H NMR and 13C NMR were predicted using the gauge-including atomic orbital theory. Results show that geometric optimization and spectral analysis confirm the presence of hydrogen bonds and conjugated systems in luteolin, indicating that its antioxidant and antitumor potential are closely associated with the electron delocalization capacity of the conjugated backbone and the stability modulation of intramolecular hydrogen bonds. DOS analysis reveals that the p-orbital-dominated conjugated system is the core of its chemical stability and antioxidant activity; functional groups such as carbonyl and hydroxyl groups participate in electronic state construction through p-orbital hybridization/conjugation, ultimately determining the molecular structure–function relationship. With a narrow HOMO–LUMO energy gap (4.37 eV), low BDE (304.27 kJ/mol), and low IP (724.44 kJ/mol), luteolin synergistically and efficiently scavenges free radicals via a hydrogen atom transfer-dominated mechanism, combined with sequential proton loss electron transfer (SPLET) and single electron transfer followed by proton transfer (SET-PT), suggesting potent antioxidant and antitumor capabilities. Based on the low BDE (304.27 kJ/mol) and the distribution of electrophilic/nucleophilic regions in MESP analysis, the phenolic hydroxyl group on ring B (O20–H30) and the carbonyl group on ring C (C3O11) are identified as potential key active sites for antioxidant and antitumor activities. This study investigates the structural characteristics, spectral properties, and key active sites of luteolin, providing a theoretical basis for its antioxidant and antitumor pharmacological effects and offering theoretical guidance for its targeted drug design.
- Open Access
- 30 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-24
The complex role and molecular mechanism of family with sequence similarity genes in cancer: a comprehensive review
The family with sequence similarity (FAM) is a family of genes with unknown functions and similar sequences. However, recent studies have reported that many FAM members play important roles in the onset and progression of cancer. Specifically, the expression of this type of gene is abnormal in tissues and cells of different types of cancer and is related to the prognosis of cancer patients. In addition, their expression regulates the proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and drug resistance of different types of cancer cells. Some members even show dual and contradictory effects in tumor-promoting or suppressing cancer. In this review, we summarized the role of FAM members in various solid tumors and sorted out the regulatory mechanism of FAM involved in tumor signal transduction, confirming their role as an important node in tumor signal transduction. Their potential as tumor markers and therapeutic targets was highlighted, offering new insights for cancer research.
- 30 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-24
Open AccessThe complex role and molecular mechanism of family with sequence similarity genes in cancer: a comprehensive review
The family with sequence similarity (FAM) is a family of genes with unknown functions and similar sequences. However, recent studies have reported that many FAM members play important roles in the onset and progression of cancer. Specifically, the expression of this type of gene is abnormal in tissues and cells of different types of cancer and is related to the prognosis of cancer patients. In addition, their expression regulates the proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and drug resistance of different types of cancer cells. Some members even show dual and contradictory effects in tumor-promoting or suppressing cancer. In this review, we summarized the role of FAM members in various solid tumors and sorted out the regulatory mechanism of FAM involved in tumor signal transduction, confirming their role as an important node in tumor signal transduction. Their potential as tumor markers and therapeutic targets was highlighted, offering new insights for cancer research.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 18, 115-141
Quercetin Inhibits Gastric Cancer Progression via FAM198B/MAPK Pathway Modulation
Background: The family with the sequence similarity 198 member B (FAM198B) has been found to contribute to the progression of gastric cancer (GC). However, the role and molecular mechanism of FAM198B in GC remains poorly understood. This work found a link between FAM198B and quercetin, and the regulatory effect of FAM198B on the MAPK pathway of GC. Methods: FAM198B expression was identified through multiple public data sets and verified in clinical tissue samples. The associations between FAM198B and the prognosis of patients with GC were analyzed via the Kaplan‒Meier plotter and Cox regression analysis. Gene set enrichment analysis, coexpressed genes, and RNA sequencing were used to explore the related functions and signaling pathways of FAM198B in GC. In vitro assays assessed the effects of FAM198B knockdown on GC cells. FAM198B was found as a quercetin target by the HERB database and in vitro assays. Results: FAM198B was highly expressed in tissues from GC patients (p< 0.001) and was positively associated with poor prognosis (p< 0.001) and immune cell infiltration in GC patients. FAM198B knockdown inhibited the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of GC cells (all p< 0.05). In addition, FAM198B knockdown decreased the phosphorylation of p-Erk1/2 and p-p38 in GC cells (all p< 0.01). Quercetin inhibited FAM198B expression and the phosphorylation of p-Erk1/2 and p-p38 in GC cells (all p< 0.05). Conclusion: Quercetin inhibits the proliferation, migration, invasion, and EMT of GC cells by inhibiting the FAM198B/MAPK signaling pathway. These discoveries lay the groundwork for developing the treatment of GC by quercetin and targeting FAM198B. In the future, more preclinical and clinical studies are needed to confirm the efficacy and safety of quercetin and target FAM198B in GC.
- 1 May 2025
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 18, 115-141
Open AccessQuercetin Inhibits Gastric Cancer Progression via FAM198B/MAPK Pathway Modulation
Background: The family with the sequence similarity 198 member B (FAM198B) has been found to contribute to the progression of gastric cancer (GC). However, the role and molecular mechanism of FAM198B in GC remains poorly understood. This work found a link between FAM198B and quercetin, and the regulatory effect of FAM198B on the MAPK pathway of GC. Methods: FAM198B expression was identified through multiple public data sets and verified in clinical tissue samples. The associations between FAM198B and the prognosis of patients with GC were analyzed via the Kaplan‒Meier plotter and Cox regression analysis. Gene set enrichment analysis, coexpressed genes, and RNA sequencing were used to explore the related functions and signaling pathways of FAM198B in GC. In vitro assays assessed the effects of FAM198B knockdown on GC cells. FAM198B was found as a quercetin target by the HERB database and in vitro assays. Results: FAM198B was highly expressed in tissues from GC patients (p< 0.001) and was positively associated with poor prognosis (p< 0.001) and immune cell infiltration in GC patients. FAM198B knockdown inhibited the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of GC cells (all p< 0.05). In addition, FAM198B knockdown decreased the phosphorylation of p-Erk1/2 and p-p38 in GC cells (all p< 0.01). Quercetin inhibited FAM198B expression and the phosphorylation of p-Erk1/2 and p-p38 in GC cells (all p< 0.05). Conclusion: Quercetin inhibits the proliferation, migration, invasion, and EMT of GC cells by inhibiting the FAM198B/MAPK signaling pathway. These discoveries lay the groundwork for developing the treatment of GC by quercetin and targeting FAM198B. In the future, more preclinical and clinical studies are needed to confirm the efficacy and safety of quercetin and target FAM198B in GC.
- Open Access
- 24 April 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-27
Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer
Objective To explore the key molecules and regulatory mechanisms of lymph node metastasis in gastric cancer. Methods The differential genes and key genes of lymph node metastasis in gastric cancer were analyzed by utilizing multiple data sets. The key genes were analyzed by GSEA analysis, transcription factor analysis, nomogram prediction model construction, immune infiltration analysis, GSVA analysis, drug sensitive analysis and single cell data analysis. Results Abnormal expression of key genes including CDRT15P1, DENND3, F2R, FNDC3B, IRAK3, MS4A2, PDK4, PKIA and activation of related signaling pathways might be the result of ultraviolet radiation-induced DNA damage, which was closely related to lymph node metastasis in gastric cancer. The key genes were regulated by a variety of transcription factors, which were strongly connected with the invasion of immune cells and the sensitivity of a variety of drugs. The nomogram prediction model, which is based on the key genes associated with lymph node metastasis and the TNM of gastric cancer, demonstrated a high level of predictive efficiency. Conclusion CDRT15P1, DENND3, F2R, FNDC3B, IRAK3, MS4A2, PDK4 and PKIA may be the key genes affecting lymph node metastasis in gastric cancer, and F2R has higher biological importance.
- 24 April 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-27
Open AccessMultiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer
Objective To explore the key molecules and regulatory mechanisms of lymph node metastasis in gastric cancer. Methods The differential genes and key genes of lymph node metastasis in gastric cancer were analyzed by utilizing multiple data sets. The key genes were analyzed by GSEA analysis, transcription factor analysis, nomogram prediction model construction, immune infiltration analysis, GSVA analysis, drug sensitive analysis and single cell data analysis. Results Abnormal expression of key genes including CDRT15P1, DENND3, F2R, FNDC3B, IRAK3, MS4A2, PDK4, PKIA and activation of related signaling pathways might be the result of ultraviolet radiation-induced DNA damage, which was closely related to lymph node metastasis in gastric cancer. The key genes were regulated by a variety of transcription factors, which were strongly connected with the invasion of immune cells and the sensitivity of a variety of drugs. The nomogram prediction model, which is based on the key genes associated with lymph node metastasis and the TNM of gastric cancer, demonstrated a high level of predictive efficiency. Conclusion CDRT15P1, DENND3, F2R, FNDC3B, IRAK3, MS4A2, PDK4 and PKIA may be the key genes affecting lymph node metastasis in gastric cancer, and F2R has higher biological importance.
- Open Access
- 17 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1571786
Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma
Introduction: Proliferating cell nuclear antigen (PCNA) is associated with the proliferation and recurrence of various cancers, and its high expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients. However, the mechanistic role of PCNA in HCC progression remains poorly understood. This study aimed to investigate how PCNA regulates DNA damage repair and cell cycle progression in HCC, with a focus on its interaction with poly (ADP-ribose) polymerase 1 (PARP1) and therapeutic implications.Methods: PCNA was targeted genetically and pharmacologically in HCC cells to assess its effects on DNA damage repair and cell cycle arrest. Protein-protein interactions between PCNA and PARP1 were validated through co-immunoprecipitation and functional assays. The sensitivity of HCC cells to the PARP1 inhibitor Olaparib was evaluated under PCNA inhibition. Synergistic effects of AOH1160 (a PCNA inhibitor) and Olaparib were tested in vitro and in vivo using proliferation assays, DNA damage quantification, and cell cycle analysis. Prognostic relevance of PCNA expression was analyzed using TCGA datasets.Results: Targeting PCNA suppressed DNA damage repair and induced cell cycle arrest in HCC cells. Mechanistically, PARP1 was identified as a downstream target of PCNA and directly interacted with PCNA. Inhibiting the expression or activity of PCNA increased the sensitivity of HCC cells to the PARP1 inhibitor, Olaparib. In addition, AOH1160 and Olaparib synergistically inhibited the proliferation, DNA damage repair and cell cycle progression of HCC cells. Elevated PCNA levels correlated with unfavorable HCC prognosis, supporting its role as a therapeutic biomarker. In vivo experiments also confirmed that repression of the PCNA/PARP1 axis significantly reduced HCC tumor growth.Discussion: This study elucidates the relationship between PCNA and PARP1 in regulating the malignant progression of HCC, and highlight the pivotal role of PCNA/PARP1 axis in DNA damage repair and cell cycle progression. The correlation between elevated PCNA levels and unfavorable prognosis underscores its potential as a therapeutic biomarker. Repression of PCNA/PARP1 axis significantly inhibits the malignant proliferation of HCC cells both in vitro and in vivo. Collectively, the study provides a mechanistic foundation for therapies targeting PCNA/PARP1 axis.
- 17 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1571786
Open AccessTargeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma
Introduction: Proliferating cell nuclear antigen (PCNA) is associated with the proliferation and recurrence of various cancers, and its high expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients. However, the mechanistic role of PCNA in HCC progression remains poorly understood. This study aimed to investigate how PCNA regulates DNA damage repair and cell cycle progression in HCC, with a focus on its interaction with poly (ADP-ribose) polymerase 1 (PARP1) and therapeutic implications.Methods: PCNA was targeted genetically and pharmacologically in HCC cells to assess its effects on DNA damage repair and cell cycle arrest. Protein-protein interactions between PCNA and PARP1 were validated through co-immunoprecipitation and functional assays. The sensitivity of HCC cells to the PARP1 inhibitor Olaparib was evaluated under PCNA inhibition. Synergistic effects of AOH1160 (a PCNA inhibitor) and Olaparib were tested in vitro and in vivo using proliferation assays, DNA damage quantification, and cell cycle analysis. Prognostic relevance of PCNA expression was analyzed using TCGA datasets.Results: Targeting PCNA suppressed DNA damage repair and induced cell cycle arrest in HCC cells. Mechanistically, PARP1 was identified as a downstream target of PCNA and directly interacted with PCNA. Inhibiting the expression or activity of PCNA increased the sensitivity of HCC cells to the PARP1 inhibitor, Olaparib. In addition, AOH1160 and Olaparib synergistically inhibited the proliferation, DNA damage repair and cell cycle progression of HCC cells. Elevated PCNA levels correlated with unfavorable HCC prognosis, supporting its role as a therapeutic biomarker. In vivo experiments also confirmed that repression of the PCNA/PARP1 axis significantly reduced HCC tumor growth.Discussion: This study elucidates the relationship between PCNA and PARP1 in regulating the malignant progression of HCC, and highlight the pivotal role of PCNA/PARP1 axis in DNA damage repair and cell cycle progression. The correlation between elevated PCNA levels and unfavorable prognosis underscores its potential as a therapeutic biomarker. Repression of PCNA/PARP1 axis significantly inhibits the malignant proliferation of HCC cells both in vitro and in vivo. Collectively, the study provides a mechanistic foundation for therapies targeting PCNA/PARP1 axis.
- 21 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1868 (5) , 130592
Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway
- 21 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1868 (5) , 130592
Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway
- 14 March 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (4) , 633-648
Ginsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis
Ginsenoside Rh2, which is extracted from ginseng, exerts antitumor activity. Recent studies suggest that Rh2 may suppress the growth of colon cancer (CC) in vitro. However, the underlying mechanism remains unclear. In this study, we identified the relative levels of miR-150-3p in CC tissues and cells by a comprehensive strategy of data mining, computational biology, and real-time reverse transcription PCR (qRT-PCR) experiments. The regulatory effects of miR-150-3p/SRCIN1 on the proliferative and invasive abilities of CC cells are evaluated by CCK-8, EdU, wound healing, and transwell assays. Cell cycle- and apoptosis-related protein levels are assessed by western blot analysis. An in vivo tumor formation assay was conducted to explore the effects of miR-150-3p on tumor growth. Furthermore, bioinformatics and dual luciferase reporter assays are applied to determine the functional binding of miRNA to mRNA of the target gene. Finally, the relationship between Rh2 and miR-150-3p was further verified in SW620 and HCT-116 cells. miR-150-3p is downregulated in CC tissues and cell lines. Functional assays indicate that the upregulation of miR-150-3p inhibits tumor growth both in vivo and in vitro. In addition, SRCIN1 is upregulated in CC and predicts a poor prognosis, and it is the direct target for miR-150-3p. Moreover, the miR-150-3p mimic decreases Topflash/Fopflash-dependent luciferase activity, resulting in the inhibition of Wnt pathway activity. Rh2 can suppress the growth of CC by increasing miR-150-3p expression. Rh2 alleviates the accelerating effect on Wnt pathway activity, cell proliferation/migration, and colony formation caused by miR-150-3p inhibition. Rh2 inhibits the miR-150-3p/SRCIN1/Wnt axis to suppress colon cancer growth.
- 14 March 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (4) , 633-648
Ginsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis
Ginsenoside Rh2, which is extracted from ginseng, exerts antitumor activity. Recent studies suggest that Rh2 may suppress the growth of colon cancer (CC) in vitro. However, the underlying mechanism remains unclear. In this study, we identified the relative levels of miR-150-3p in CC tissues and cells by a comprehensive strategy of data mining, computational biology, and real-time reverse transcription PCR (qRT-PCR) experiments. The regulatory effects of miR-150-3p/SRCIN1 on the proliferative and invasive abilities of CC cells are evaluated by CCK-8, EdU, wound healing, and transwell assays. Cell cycle- and apoptosis-related protein levels are assessed by western blot analysis. An in vivo tumor formation assay was conducted to explore the effects of miR-150-3p on tumor growth. Furthermore, bioinformatics and dual luciferase reporter assays are applied to determine the functional binding of miRNA to mRNA of the target gene. Finally, the relationship between Rh2 and miR-150-3p was further verified in SW620 and HCT-116 cells. miR-150-3p is downregulated in CC tissues and cell lines. Functional assays indicate that the upregulation of miR-150-3p inhibits tumor growth both in vivo and in vitro. In addition, SRCIN1 is upregulated in CC and predicts a poor prognosis, and it is the direct target for miR-150-3p. Moreover, the miR-150-3p mimic decreases Topflash/Fopflash-dependent luciferase activity, resulting in the inhibition of Wnt pathway activity. Rh2 can suppress the growth of CC by increasing miR-150-3p expression. Rh2 alleviates the accelerating effect on Wnt pathway activity, cell proliferation/migration, and colony formation caused by miR-150-3p inhibition. Rh2 inhibits the miR-150-3p/SRCIN1/Wnt axis to suppress colon cancer growth.
- 14 February 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (4) , 649-660
lncRNA ELFN1-AS1 promotes proliferation, migration and invasion and suppresses apoptosis in colorectal cancer cells by enhancing G6PD activity
Tumour cells change their metabolic patterns to support high proliferation rates and cope with oxidative stress. The lncRNA ELFN1-AS1 is highly expressed in a wide range of cancers and is essential to the proliferation and apoptosis of tumour cells. Nevertheless, its function in the metabolic reprogramming of tumour cells is unclear. Here we show that ELFN1-AS1 promotes glucose consumption as well as lactate and NADPH production. Database searching, bioinformatics analysis, RNA immunoprecipitation (RIP) and RNA pull-down assays show that ELFN1-AS1 enhances glucose-6-phosphate dehydrogenase ( G6PD) expression and activates the pentose phosphate pathway (PPP) by promoting TP53 degradation. In addition, luciferase reporter assay and chromatin immunoprecipitation (ChIP) show that YY1 binds to the ELFN1-AS1 promoter to promote transcriptional activation of ELFN1-AS1. Consistent with the in vitro experiments, knockdown of ELFN1-AS1 impedes the growth of tumours transplanted into mice by inhibiting the expression of G6PD. In conclusion, this study reveals that ELFN1-AS1 activates the PPP, and validates the regulatory role of the YY1/ ELFN1-AS1/ TP53/ G6PD axis in colorectal cancer.
- 14 February 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (4) , 649-660
lncRNA ELFN1-AS1 promotes proliferation, migration and invasion and suppresses apoptosis in colorectal cancer cells by enhancing G6PD activity
Tumour cells change their metabolic patterns to support high proliferation rates and cope with oxidative stress. The lncRNA ELFN1-AS1 is highly expressed in a wide range of cancers and is essential to the proliferation and apoptosis of tumour cells. Nevertheless, its function in the metabolic reprogramming of tumour cells is unclear. Here we show that ELFN1-AS1 promotes glucose consumption as well as lactate and NADPH production. Database searching, bioinformatics analysis, RNA immunoprecipitation (RIP) and RNA pull-down assays show that ELFN1-AS1 enhances glucose-6-phosphate dehydrogenase ( G6PD) expression and activates the pentose phosphate pathway (PPP) by promoting TP53 degradation. In addition, luciferase reporter assay and chromatin immunoprecipitation (ChIP) show that YY1 binds to the ELFN1-AS1 promoter to promote transcriptional activation of ELFN1-AS1. Consistent with the in vitro experiments, knockdown of ELFN1-AS1 impedes the growth of tumours transplanted into mice by inhibiting the expression of G6PD. In conclusion, this study reveals that ELFN1-AS1 activates the PPP, and validates the regulatory role of the YY1/ ELFN1-AS1/ TP53/ G6PD axis in colorectal cancer.